Labcorp Owes Ravgen $100 Million More Over Prenatal Test Patents

Laboratory Corporation of America Holdings must pay another $100 million to Ravgen Inc. on top of the $272.5 million in damages a Texas federal jury awarded the fetal test maker last year, US District Judge Alan Albright of Waco ruled Friday.

Albright boosted damages because Labcorp intentionally co-opted Ravgen’s patented revolutionary non-invasive prenatal testing process that uses cell-free fetal DNA from the mother’s blood to screen for genetic abnormalities, like Down syndrome.

Trial testimony showed Labcorp executives even privately wondered why Ravgen waited until October 2020 to sue over products they’d introduced in 2012 and 2014.

Jurors in the Western ...